All News

CHICAGO - Abbott Laboratories, Hoescht Marion Roussel, Pharmacia & Upjohn and Rhone-Poulenc Rorer followed the precedent set by 11 other pharmaceutical manufacturers last month when they tentatively agreed to settle a class-action lawsuit brought against them by Walgreen Co. and other retail pharmacies.

One managed care organization is gambling that combining technology and medicine will improve the health of its plan members, and improve its disease management efforts.

Why are cancer researchers intensifying their focus on finding ways to make cancer patients feel better as opposed to solely finding ways to treat their disease? Datamonitor, a New York-based market research and consulting firm surveyed a score of patients, medical professionals, representatives of the pharmaceutical industry and experts in the quality-of-life research field to answer this question.

Balancing a career, family and volunteer work is no easy task, but Pennie Vanderlin, a comprehensive care rep for Zeneca Pharmaceuticals, has found that enjoyment, hard work and a good support system are the keys to success.

Despite raising premium revenue by 4%, health maintenance organizations in Minnesota lost $47.2 million on commercial operations in 1997, according to the spring edition of the Minnesota Managed Care Review.

Pharmaceutical companies are developing 85 new medicines for mental disorders, according to a new survey released by Washington-based Pharmaceutical Research and Manufacturers of America.

"It's the little things that make a big difference." You know that's true of your sales relationships, but that old adage also applies to your e-mails and memos.

The Food and Drug Administration proposed new rules that will provide pharmaceutical companies more latitude in promoting off-label uses of medicines, biologics and medical devices.

A majority of American patients are pleased with their physicians, according to a new survey released by the Pfizer Medical Humanities Initiative.

The launch of Viagra, Pfizer's new oral medication for erectile dysfunction, invigorated an otherwise sleepy sexual dysfunction market, sparked debate among health plan insurers and established itself as the most successful launch ever.

If it seems like there are more pharmaceutical sales reps in the field this year than there have been in the past, it's because there are.

Contrary to popular opinion, possession of knowledge is not power. Utilization of knowledge is power.

Wholesaler preferred generics programs encourage price competition that benefits Medicare and Medicaid programs and, therefore, do not violate anti-kickback statutes, according to an advisory opinion released by the Health and Human Services Office of the Inspector General in April.

Rep must not forget what they should NOT do on a sales call, so they don't shoot ourselves in the foot on the way in or out of a doctor's office.

The number of commercially insured patients who used indemnity plans in 1997 was drastically lower than it was in 1993, according to a new report from Mountain View, CA-based strategic research firm Frost & Sullivan.

A prescription drug that has been on the market for the past 20 years may actually prevent breast cancer, according to new research.

Adverse drug reactions in hospitals could be a leading cause of death in the United States, according to a controversial study published in the April 14 issue of The Journal of American Medical Association.

The rate of sales growth in North America and selected international markets grew by 6% from February 1997 to January 1998, according to a recent "Drug Monitor" report from IMS Global Services. Final sales closed at $181 billion.

Last November, President Clinton formally signed into law the Food and Drug Administration Modernization Act, sweeping bipartisan congressional legislation focused on reforming the agency's regulation of food, drugs, medical devices and cosmetics. Overall, the new law is considered a triumph by both the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization because it embraces many of the FDA legislative reform recommendations the industries had proposed to streamline the drug regulatory process.